Chimeric antigen receptor (CAR) T cell therapy stands as a transformative advancement in immunotherapy, triumphing against hematological malignancies and, increasingly, autoimmune disorders. After a decade of relatively modest results for solid tumors, recent clinical trials and patient reports have also started to yield promising outcomes in glioblastoma and other challenging solid tumor entities. This Perspective seeks to explore the reasons behind these latest achievements and discusses how they can be sustained and expanded through different strategies involving CAR engineering and synthetic biology. Furthermore, we critically analyze how these breakthroughs can be leveraged to maintain momentum and broaden the therapeutic impact of CAR T cells across a variety of solid tumor landscapes.

嵌合抗原受体 （CAR） T 细胞疗法是免疫疗法的变革性进步，战胜了血液系统恶性肿瘤和越来越多的自身免疫性疾病。在实体瘤取得十年相对温和的结果之后，最近的临床试验和患者报告也开始在胶质母细胞瘤和其他具有挑战性的实体瘤实体中产生有希望的结果。本观点旨在探讨这些最新成就背后的原因，并讨论如何通过涉及 CAR 工程和合成生物学的不同策略来维持和扩展这些成就。此外，我们批判性地分析了如何利用这些突破来保持势头并扩大 CAR T 细胞在各种实体瘤景观中的治疗影响。